SERENITY I & II Phase 3 Trials Topline Results

BioXcel Therapeutics Inc. published this content on July 20, 2020, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on May 07, 2025 at 11:13 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at support@pubt.io